Sarah Buckley

7.2k total citations
75 papers, 1.6k citations indexed

About

Sarah Buckley is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Sarah Buckley has authored 75 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 31 papers in Genetics and 15 papers in Oncology. Recurrent topics in Sarah Buckley's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers), Acute Myeloid Leukemia Research (22 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Sarah Buckley is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers), Acute Myeloid Leukemia Research (22 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Sarah Buckley collaborates with scholars based in United States, United Kingdom and Italy. Sarah Buckley's co-authors include Roland B. Walter, Brent L. Wood, Frederick R. Appelbaum, John M. Pagel, Brenda M. Sandmaier, Boglarka Gyurkocza, Elihu H. Estey, Megan Othus, F R Appelbaum and Barry E. Storer and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sarah Buckley

69 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Buckley United States 21 1.0k 423 366 358 282 75 1.6k
A O’Farrell Ireland 14 512 0.5× 146 0.3× 223 0.6× 437 1.2× 304 1.1× 39 1.4k
Samart Pakakasama Thailand 25 472 0.5× 408 1.0× 359 1.0× 434 1.2× 334 1.2× 130 1.6k
Bernward Zeller Norway 27 1.4k 1.3× 790 1.9× 191 0.5× 354 1.0× 339 1.2× 86 2.2k
Luca Cordero di Montezemolo Italy 25 158 0.2× 233 0.6× 351 1.0× 452 1.3× 208 0.7× 59 1.7k
Anders Jørgen Svendsen Denmark 24 332 0.3× 76 0.2× 128 0.3× 233 0.7× 129 0.5× 52 1.8k
M. Horowitz United States 16 269 0.3× 83 0.2× 83 0.2× 165 0.5× 244 0.9× 32 1.2k
Sau Wan Kan United Kingdom 11 575 0.6× 110 0.3× 151 0.4× 184 0.5× 215 0.8× 13 1.2k
Audrey A. Dawson United Kingdom 19 327 0.3× 97 0.2× 168 0.5× 167 0.5× 252 0.9× 77 1.1k
Larry P. Ebbert United States 15 390 0.4× 138 0.3× 88 0.2× 178 0.5× 312 1.1× 22 1.3k
S Meller United Kingdom 21 370 0.4× 194 0.5× 102 0.3× 77 0.2× 176 0.6× 42 1.0k

Countries citing papers authored by Sarah Buckley

Since Specialization
Citations

This map shows the geographic impact of Sarah Buckley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Buckley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Buckley more than expected).

Fields of papers citing papers by Sarah Buckley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Buckley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Buckley. The network helps show where Sarah Buckley may publish in the future.

Co-authorship network of co-authors of Sarah Buckley

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Buckley. A scholar is included among the top collaborators of Sarah Buckley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Buckley. Sarah Buckley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weeks, Lachelle D., Danielle Hammond, Sinisa Savic, et al.. (2025). Establishing a consensus definition of VEXAS flare for clinical research. Lara D. Veeken. 65(2).
2.
Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2024). Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology. 114(2). 238–247. 3 indexed citations
3.
Vachhani, Pankit, et al.. (2024). Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.. Journal of Clinical Oncology. 42(16_suppl). 6578–6578.
4.
Oh, Stephen T., et al.. (2024). MPN-497 Impact of Pacritinib on Symptoms in Thrombocytopenic Myelofibrosis Patients Who Require Red Blood Cell Transfusion. Clinical Lymphoma Myeloma & Leukemia. 24. S436–S436. 1 indexed citations
5.
Vachhani, Pankit, et al.. (2024). MPN-470 Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia. Clinical Lymphoma Myeloma & Leukemia. 24. S434–S434.
6.
Gagelmann, Nico, Prithviraj Bose, Vikas Gupta, et al.. (2024). Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib. Clinical Lymphoma Myeloma & Leukemia. 24(11). 796–803. 3 indexed citations
7.
Oh, Stephen T., Ruben A. Mesa, Claire Harrison, et al.. (2023). Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Advances. 7(19). 5835–5842. 39 indexed citations
8.
Vachhani, Pankit, Abdulraheem Yacoub, Elie Traer, et al.. (2023). Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies. Blood. 142(Supplement 1). 4554–4554. 1 indexed citations
9.
Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2023). Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.. Journal of Clinical Oncology. 41(16_suppl). 7018–7018. 1 indexed citations
10.
Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2023). P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS. HemaSphere. 7(S3). e44640da–e44640da.
11.
Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2023). MPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis. Clinical Lymphoma Myeloma & Leukemia. 23. S382–S383. 1 indexed citations
12.
Buckley, Sarah, Mary‐Elizabeth M. Percival, Megan Othus, et al.. (2018). A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leukemia & lymphoma. 60(4). 1023–1029. 2 indexed citations
13.
Halpern, Anna B., Megan Othus, Emily M. Huebner, et al.. (2018). Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 32(11). 2352–2362. 34 indexed citations
14.
Lee, Stephanie J., Lynn Onstad, Eric J. Chow, et al.. (2018). Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica. 103(9). 1535–1541. 56 indexed citations
15.
Vaughn, Jennifer, Sarah Buckley, & Roland B. Walter. (2016). Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations. Leukemia Research. 45. 53–58. 41 indexed citations
16.
Mark, Nicholas M., et al.. (2015). Diagnostic Utility of Food Terminology: Culinary Clues for the Astute Diagnostician. The American Journal of Medicine. 128(9). 933–935. 2 indexed citations
17.
Walter, Roland B., Brenda M. Sandmaier, Barry E. Storer, et al.. (2014). Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. Biology of Blood and Marrow Transplantation. 21(2). 373–378. 30 indexed citations
18.
Walter, Roland B., Sarah Buckley, & Emily White. (2012). Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study. Annals of Oncology. 24(5). 1370–1377. 14 indexed citations
19.
Guérin, Suzanne, Sarah Buckley, John McEvoy, John Hillery, & Philip Dodd. (2009). The psychometric properties of the Attention–Distraction, Inhibition–Excitation Classroom Assessment Scale (ADIECAS) in a sample of children with moderate and severe intellectual disabilities. Research in Developmental Disabilities. 30(4). 727–734. 4 indexed citations
20.
O’Leary, Clare, et al.. (2002). Celiac disease and irritable bowel-type symptoms. The American Journal of Gastroenterology. 97(6). 1463–1467. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A O’Farrell Breakdown of academic impact, for papers by Samart Pakakasama Breakdown of academic impact, for papers by Bernward Zeller Breakdown of academic impact, for papers by Luca Cordero di Montezemolo Breakdown of academic impact, for papers by Anders Jørgen Svendsen Breakdown of academic impact, for papers by M. Horowitz Breakdown of academic impact, for papers by Sau Wan Kan Breakdown of academic impact, for papers by Audrey A. Dawson Breakdown of academic impact, for papers by Larry P. Ebbert Breakdown of academic impact, for papers by S Meller
Rankless by CCL
2026